Merck & Co., Inc. Grants License to Laboratory Corporation of America Holdings (LabCorp) for Development of Test To Potentially Identify Patients Likely to Respond to Hepatitis C Therapy

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck today announced a non-exclusive license agreement with Laboratory Corporation of America® Holdings (LabCorp®) for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus (HCV) infection to peginterferon alpha-based therapy.

MORE ON THIS TOPIC